Asthma is a chronic inflammatory disorder of the airways that leads to acute symptoms,
exacerbations and sometimes, for a small part of the asthmatic population, fatal or near-fatal …

Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival,
and degranulation of eosinophils. Indeed, during the last years, significant advances have …

Anti-interleukin-5 antibody therapy in asthma and allerges : Current Opinion in Allergy and
Clinical Immunology Anti-interleukin-5 antibody therapy in asthma and allerges : Current …

The definition of asthma has changed considerably in recent years, to the extent that asthma
is no longer considered a single disease but a heterogeneous disorder that includes several …

Asthma is a chronic and heterogeneous disease, which is defined as severe disease
whenever it requires treatment with a high dose of inhaled corticosteroids plus a second …

Two recent phase III trials in patients with severe eosinophilic asthma have shown that anti-
interleukin 5 (IL-5) therapy with mepolizumab reduces the frequency of asthma attacks …

The current developments of the new biological drugs targeting interleukin 5 (IL‐5) and IL‐5
receptor allowed to expand the treatment options for severe hypereosinophilic asthma …

Elevated numbers of blood and tissue eosinophils are present in allergic diseases and
experimental evidence suggests that eosinophils play an important pathogenic role in these …

Inconsistent results have been reported regarding IL‐5 blockade treatment in asthma. There
were no direct between‐treatment comparisons. Only differences between each drug and …

Abstract Background Interleukin-5 (IL-5) antibodies represent a promising therapeutic option
for patients with severe eosinophilic asthma. To date, no official treatment response criteria …